disease-modifying antirheumatic drugs

dis·ease-mod·i·fy·ing an·ti·rheu·ma·tic drugs

(DMARD) (di-zēz'mod'i-fī-ing an'tē-rū-mat'ik drŭgz)
Agents that apparently alter the course and progression of rheumatoid arthritis, as opposed to more rapidly acting substances that suppress inflammation and decrease pain, but do not prevent cartilage or bone erosion or progressive disability.

disease-modifying antirheumatic drugs

; DMARDs group of cytokine-inhibiting agents, used singly or in combination, to minimize and/or control inflammation, joint swelling and tissue destruction characteristic of rheumatoid disease, reducing incidence of irreversible joint damage; e.g. penicillamine, gold salts, antimalarials (chloroquine and hydroxychloroquine), drugs affecting the immune response (azathioprine, methotrexate and enteracept), sulfasalazine and corticosteroids

dis·ease-mod·i·fy·ing an·ti·rheu·ma·tic drugs

(DMARD) (di-zēz'mod'i-fī-ing an'tē-rū-mat'ik drŭgz)
Agents that alter the course and progression of rheumatoid arthritis.
References in periodicals archive ?
Scientists analysed the records of patients taking disease-modifying antirheumatic drugs (DMARDs) and those who were not.
Meanwhile, patients continue to take their previous medicines - traditional disease-modifying antirheumatic drugs (DMARDs).
NYSE: PFE) approval for Xeljanz 5 mg twice daily and Xeljanz XR (tofacitinib) extended release 11 mg once daily for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs), the company said.
announced today that the United States Food and Drug Administration (FDA) has approved XELJANZ 5 mg twice daily (BID) and XELJANZ XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
We need to do more, think differently, think outside the box" of relying primarily on disease-modifying antirheumatic drugs, especially biological drugs, to resolve symptoms in PsA patients.
The findings are encouraging because patients with rheumatoid arthritis have a higher risk of developing shingles than other adults, and tofacitinib and certain other disease-modifying antirheumatic drugs are thought to further increase this risk.
Most participants in the study had longstanding RA and were taking disease-modifying antirheumatic drugs.
A human monoclonal antibody, Kevzara is indicated for use in patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
A new study confirms that early treatment of rheumatoid arthritis (RA) with low-dose steroids, combined with disease-modifying antirheumatic drugs (DMARDs), taken at the lowest possible dose and for the shortest period of time, is safe and effective.
The institute is recommending the use of Cosentyx when a patient is suffering from peripheral arthritis with three or more tender joints and three or more swollen joints, and has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either as a monotherapy or in combination.
The researchers matched 59,627 patients who received the herpes zoster vaccine with 119,254 unvaccinated patients, based on age, sex, race, calendar year, autoimmune disease type, and use of autoimmune drugs (biologies, disease-modifying antirheumatic drugs, and glucocorticoids).
Researchers compared the health records of more than 11,000 RA patients taking TNFis with the records of about 3,000 RA patients taking synthetic disease-modifying antirheumatic drugs (sDMARDs), another common RA treatment.